Adaptimmune Therapeutics plc (NASDAQ:ADAP) went down by -5.46% from its latest closing price compared to the recent 1-year high of $13.40. The company’s stock price has collected 2.08% of gains in the last five trading sessions. Press Release reported on 11/20/20 that Adaptimmune to Showcase Market Potential for SPEAR T-cell Portfolio and Pipeline with Multiple Cell Therapy Platforms During Virtual Investor Day
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
Is It Worth Investing in Adaptimmune Therapeutics plc (NASDAQ :ADAP) Right Now?
Plus, the 36-month beta value for ADAP is at 2.22. Opinions of the stock are interesting as 4 analysts out of 8 who provided ratings for Adaptimmune Therapeutics plc declared the stock was a “buy,” while 0 rated the stock as “overweight,” 4 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $11.33. ADAP currently public float of 11.25M and currently shorts hold a 25.11% ratio of that float. Today, the average trading volume of ADAP was 1.90M shares.
ADAP’s Market Performance
ADAP stocks went up by 2.08% for the week, with a monthly jump of 45.43% and a quarterly performance of -29.55%, while its annual performance rate touched 47.62%. The volatility ratio for the week stands at 6.82% while the volatility levels for the past 30 days are set at 8.49% for Adaptimmune Therapeutics plc. The simple moving average for the period of the last 20 days is 13.44% for ADAP stocks with a simple moving average of -12.58% for the last 200 days.
Analysts’ Opinion of ADAP
Many brokerage firms have already submitted their reports for ADAP stocks, with Mizuho repeating the rating for ADAP by listing it as a “Neutral.” The predicted price for ADAP in the upcoming period, according to Mizuho is $3 based on the research report published on April 22nd of the previous year 2020.
ADAP Trading at 19.25% from the 50-Day Moving Average
After a stumble in the market that brought ADAP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -56.04% of loss for the given period.
Volatility was left at 8.49%, however, over the last 30 days, the volatility rate increased by 6.82%, as shares surge +47.25% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +30.02% upper at present.
During the last 5 trading sessions, ADAP rose by +2.08%, which changed the moving average for the period of 200-days by +106.67% in comparison to the 20-day moving average, which settled at $5.29. In addition, Adaptimmune Therapeutics plc saw 9.28% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ADAP starting from Lunger John, who sale 1,058 shares at the price of $6.15 back on Jan 12. After this action, Lunger John now owns 1,767 shares of Adaptimmune Therapeutics plc, valued at $6,509 using the latest closing price.
Bertrand William C JR, the Chief Operating Officer of Adaptimmune Therapeutics plc, sale 2,234 shares at $6.15 during a trade that took place back on Jan 12, which means that Bertrand William C JR is holding 3,768 shares at $13,744 based on the most recent closing price.
Stock Fundamentals for ADAP
Current profitability levels for the company are sitting at:
- -13713.28 for the present operating margin
The net margin for Adaptimmune Therapeutics plc stands at -12225.04. The total capital return value is set at -78.03, while invested capital returns managed to touch -70.01. Equity return is now at value -44.90, with -33.70 for asset returns.
Based on Adaptimmune Therapeutics plc (ADAP), the company’s capital structure generated 20.59 points at debt to equity in total, while total debt to capital is 17.08. Total debt to assets is 14.02, with long-term debt to equity ratio resting at 18.58. Finally, the long-term debt to capital ratio is 15.40.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
When we switch over and look at the enterprise to sales, we see a ratio of 217.47, with the company’s debt to enterprise value settled at 0.41. The receivables turnover for the company is 0.06 and the total asset turnover is 0.00. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.51.
